{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T08:26:20Z","timestamp":1784795180841,"version":"3.55.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,3,21]],"date-time":"2018-03-21T00:00:00Z","timestamp":1521590400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1038\/s41375-018-0099-8","type":"journal-article","created":{"date-parts":[[2018,4,4]],"date-time":"2018-04-04T02:04:07Z","timestamp":1522807447000},"page":"1414-1420","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Treatment approaches and outcomes in plasmacytomas: analysis using a national dataset"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6148-5177","authenticated-orcid":false,"given":"Gaurav","family":"Goyal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam C.","family":"Bartley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shealeigh","family":"Funni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Inselman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilay D.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariela L.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneel A.","family":"Ashrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1860-2424","authenticated-orcid":false,"given":"Urshila","family":"Durani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrukh K.","family":"Hashmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustaqeem A.","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis K.","family":"Buadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8284-3495","authenticated-orcid":false,"given":"Ronald S.","family":"Go","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Kyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson I.","family":"Gonsalves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,21]]},"reference":[{"key":"99_CR1","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/j.1365-2141.2008.07421.x","volume":"144","author":"GM Dores","year":"2009","unstructured":"Dores GM, Landgren O, McGlynn KA, Curtis RE, Linet MS, Devesa SS. Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the United States, 1992\u20132004. Br J Haematol. 2009;144:86\u201394.","journal-title":"Br J Haematol"},{"key":"99_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-3015-5","volume":"17","author":"N Thumallapally","year":"2017","unstructured":"Thumallapally N, Meshref A, Mousa M, Terjanian T. Solitary plasmacytoma: population-based analysis of survival trends and effect of various treatment modalities in the USA. BMC Cancer. 2017;17:13.","journal-title":"BMC Cancer"},{"key":"99_CR3","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1002\/1097-0142(19920315)69:6<1513::AID-CNCR2820690633>3.0.CO;2-X","volume":"69","author":"J Holland","year":"1992","unstructured":"Holland J, Trenkner DA, Wasserman TH, Fineberg B. Plasmacytoma. Treatment results and conversion to myeloma. Cancer. 1992;69:1513\u20137.","journal-title":"Cancer"},{"key":"99_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-6-118","volume":"6","author":"D Knobel","year":"2006","unstructured":"Knobel D, Zouhair A, Tsang RW, Poortmans P, Belkacemi Y, Bolla M, et al. Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study. BMC Cancer. 2006;6:118.","journal-title":"BMC Cancer"},{"key":"99_CR5","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1200\/JCO.1983.1.4.255","volume":"1","author":"MA Knowling","year":"1983","unstructured":"Knowling MA, Harwood AR, Bergsagel DE. Comparison of extramedullary plasmacytomas with solitary and multiple plasma cell tumors of bone. J Clin Oncol. 1983;1:255\u201362.","journal-title":"J Clin Oncol"},{"key":"99_CR6","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1002\/ajh.23201","volume":"87","author":"R Warsame","year":"2012","unstructured":"Warsame R, Gertz MA, Lacy MQ, Kyle RA, Buadi F, Dingli D, et al. Trends and outcomes of modern staging of solitary plasmacytoma of bone. Am J Hematol. 2012;87:647\u201351.","journal-title":"Am J Hematol"},{"key":"99_CR7","doi-asserted-by":"publisher","first-page":"e229","DOI":"10.3324\/haematol.2016.157768","volume":"102","author":"J Weberpals","year":"2017","unstructured":"Weberpals J, Pulte D, Jansen L, Luttmann S, Holleczek B, Nennecke A, et al. Survival of patients with lymphoplasmacytic lymphoma and solitary plasmacytoma in Germany and the United States of America in the early 21st century. Haematologica. 2017;102:e229\u2013e232.","journal-title":"Haematologica"},{"key":"99_CR8","unstructured":"National Comprehensive Cancer Network. Multiple Myeloma (Version 3. 2017). Accessed July 24th, 2017. \n                    https:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/myeloma.pdf\n                    \n                  ."},{"key":"99_CR9","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1037\/a0016973","volume":"14","author":"C Strobl","year":"2009","unstructured":"Strobl C, Malley J, Tutz G. An introduction to recursive partitioning: rationale, application, and characteristics of classification and regression trees, bagging, and random forests. Psychol Methods. 2009;14:323\u201348.","journal-title":"Psychol Methods"},{"key":"99_CR10","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1111\/j.1365-2141.2004.04834.x","volume":"124","author":"R Soutar","year":"2004","unstructured":"Soutar R, Lucraft H, Jackson G, Reece A, Bird J, Low E, et al. Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma. Br J Haematol. 2004;124:717\u201326.","journal-title":"Br J Haematol"},{"key":"99_CR11","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/0360-3016(89)90008-4","volume":"16","author":"DA Frassica","year":"1989","unstructured":"Frassica DA, Frassica FJ, Schray MF, Sim FH, Kyle RA. Solitary plasmacytoma of bone: Mayo Clinic experience. Int J Radiat Oncol Biol Phys. 1989;16:43\u201348.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"99_CR12","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ijrobp.2005.06.039","volume":"64","author":"M Ozsahin","year":"2006","unstructured":"Ozsahin M, Tsang RW, Poortmans P, Belkacemi Y, Bolla M, Dincbas FO, et al. Outcomes and patterns of failure in solitary plasmacytoma: a multicenter Rare Cancer Network study of 258 patients. Int J Radiat Oncol Biol Phys. 2006;64:210\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"99_CR13","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.ijrobp.2010.11.037","volume":"82","author":"R Sasaki","year":"2012","unstructured":"Sasaki R, Yasuda K, Abe E, Uchida N, Kawashima M, Uno T, et al. Multi-institutional analysis of solitary extramedullary plasmacytoma of the head and neck treated with curative radiotherapy. Int J Radiat Oncol Biol Phys. 2012;82:626\u201334.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"99_CR14","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.ijrobp.2005.09.019","volume":"64","author":"L Tournier-Rangeard","year":"2006","unstructured":"Tournier-Rangeard L, Lapeyre M, Graff-Caillaud P, Mege A, Dolivet G, Toussaint B, et al. Radiotherapy for solitary extramedullary plasmacytoma in the head-and-neck region: a dose greater than 45 Gy to the target volume improves the local control. Int J Radiat Oncol Biol Phys. 2006;64:1013\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41375-018-0099-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-018-0099-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-018-0099-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:33:57Z","timestamp":1684618437000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-018-0099-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,21]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["99"],"URL":"https:\/\/doi.org\/10.1038\/s41375-018-0099-8","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,21]]},"assertion":[{"value":"4 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"SK has research support for clinical trials from Abbott Laboratories, Amgen Inc.; Celgene Corporation; Janssen Pharmaceutica Products, LP; Novartis Pharmaceuticals Corporation; sanofi-aventis US; and Takeda Pharmaceuticals North America Inc. He serves as a scientific advisor for Amgen Inc., Bristol-Myers Squibb Company, Celgene Corporation, GlycoMimetics, Janssen Pharmaceutica Products, LP, sanofi-aventis US, and Takeda Pharmaceuticals North America Inc. The other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}